CRP and metabolic syndrome: We found that CysC emerged as the most robust predictor across all-cause and CVD mortality outcomes in patients with MetS, demonstrating superior predictive efficacy compared to eGFR, urea nitrogen, creatinine, uric acid, and CRP.